Allergan signs $1.5 billion deal with Molecular Partners
pharmafile | August 22, 2012 | News story | Research and Development, Sales and Marketing | Allergan, Molecular Partners, eye diseases
Allergan has signed a deal potentially worth $1.5 billion with Molecular Partners to develop new drugs for certain eye diseases.
This is a significant expansion of their existing relations of DARPin-based products for the treatment of serious ophthalmic diseases.
DARPins are a class of biological drugs that work similarly to monoclonal antibodies, but with the advantages of small molecules, including high stability and low-cost production, say Molecular Partners.
The Swiss firm will receive combined upfront payments of $62.5 million under the two agreements, and is eligible to receive additional success-based payments of up to $1.4 billion.
The first is an exclusive license agreement for the design, development and commercialisation of a dual anti-VEGF-A/PDGF-B DARPin treatment for the eye condition age-related macular degeneration (AMD).
Under the license agreement, Allergan and Molecular Partners will work together to develop MP0260 through human proof of concept, at which point Molecular Partners has the option to co-fund Allergan’s development costs in exchange for a significant royalty step up.
The second is an exclusive discovery alliance agreement under which the firms will collaborate to design and develop DARPins against selected targets that are implicated in causing serious diseases of the eye.
During the research phase, Allergan has the right to exercise three options to exclusively license collaboration compounds for ophthalmology.
Bigger sales
Allergan already has a number of established products to treat a variety of eye conditions including glaucoma, dry eye, and external eye diseases.
But if it can tap into the AMD market, it will be opening itself up to blockbuster sales. Novartis’ Lucentis, which is licensed for wet AMD as well as other licences, made over $1 billion in sales last year. Its new competitor Eylea is also expected to reach blockbuster sales.
Lucentis and Eylea work as a VEGF Eye Trap, but MP0260 works differently by also inhibiting PDGF, another signalling condition that can cause proliferative vitreoretinopathy, a key element in AMD.
Scott Whitcup, chief scientific officer of Allergan, said: “As a leader in ophthalmology, Allergan is committed to developing new treatments for serious eye diseases like AMD.
“We look forward to further developing a novel therapy that blocks both VEGF and PDGF, as a potential way to improve vision in patients with wet AMD.”
Patrick Amstutz, chief business officer of Molecular Partners, said: “This is an important step forward in our strategy to build on strong partnerships with the leaders in a therapeutic area.
“DARPins are potent biologics which may address significant unmet medical needs in large patient populations in various disease areas.”
Allergan is best known for its Botox treatment, which was originally licensed as an anti-wrinkle treatment, but in recent years Allergan has gained new indications for the treatment to broaden its use.
This includes approval from the Medicines and Healthcare Products Regulatory in 2010 for use as a headache prophylaxis, and last year’s FDA approval for use in patients with urinary incontinence.
Ben Adams
Related Content

FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …

$63bn Allergan/AbbVie merger review could be delayed by coronavirus
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …

Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
New Phase 3 data has been released showing that both 50mg and 100mg doses of …






